Valneva SE (VALN) Interest Expenses (2020 - 2026)
Valneva SE (VALN) posted quarterly Interest Expenses of -$5.8 million for Q1 2026, up 14.84% year-on-year from -$5.0 million in Q1 2025, and down 120.7% on a QoQ basis from $28.0 million in Q4 2025.
Valneva SE (VALN) Interest Expenses (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Interest Expenses for 7 consecutive years, with -$5.8 million the latest figure, recorded in Q1 2026.
- Quarterly Interest Expenses rose 14.84% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.5 million (up 74.81% YoY) and the FY2025 annual result came in at $47.7 million, up 74.58% from the prior year.
- Interest Expenses slipped to -$5.8 million in Q1 2026 per VALN's latest filing, from $28.0 million in the prior quarter.
- Over the last five years, Interest Expenses for VALN reached as high as $40.7 million in Q4 2023 and fell as low as -$24.3 million in Q3 2023.
- A 5-year average of $6.8 million and a median of $6.5 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses plunged 406.19% — and 2023, when it jumped 501.47%.
- Year by year, Interest Expenses stood at $36.9 million in 2022, then rose by 10.33% to $40.7 million in 2023, then plunged by 82.4% to $7.2 million in 2024, then surged by 290.48% to $28.0 million in 2025, then sank by 120.7% to -$5.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$5.8 million, $28.0 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -5.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.79 Mn |
| Mar 31, 2026 | -5.79 Mn |
| Dec 31, 2025 | 27.99 Mn |
| Dec 31, 2025 | 27.99 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Sep 30, 2025 | 6.50 Mn |
| Jun 30, 2025 | 18.75 Mn |
| Jun 30, 2025 | 18.75 Mn |
| Mar 31, 2025 | -6.80 Mn |
| Mar 31, 2025 | -6.80 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Sep 30, 2024 | 6.51 Mn |
| Sep 30, 2024 | 6.51 Mn |
| Jun 30, 2024 | 20.27 Mn |
| Jun 30, 2024 | 20.27 Mn |
| Mar 31, 2024 | -8.02 Mn |
| Mar 31, 2024 | -8.02 Mn |
| Dec 31, 2023 | 40.74 Mn |
| Dec 31, 2023 | 40.74 Mn |